Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Fernö M[au]:

A molecular taxonomy for urothelial carcinoma. Sjödahl G et al. Clin Cancer Res. (2012)

Immune gene expression and response to chemotherapy in advanced breast cancer. Foukakis T et al. Br J Cancer. (2018)

Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors. Sjöström M et al. Breast Cancer Res. (2018)

Search results

Items: 1 to 50 of 245

1.

Clinicogenomic Radiotherapy Classifier Predicting the Need for Intensified Locoregional Treatment After Breast-Conserving Surgery for Early-Stage Breast Cancer.

Sjöström M, Chang SL, Fishbane N, Davicioni E, Zhao SG, Hartman L, Holmberg E, Feng FY, Speers CW, Pierce LJ, Malmström P, Fernö M, Karlsson P.

J Clin Oncol. 2019 Oct 16:JCO1900761. doi: 10.1200/JCO.19.00761. [Epub ahead of print]

PMID:
31618132
2.

---Comprehensive transcriptomic profiling identifies breast cancer patients who may be spared adjuvant systemic therapy.

Sjöström M, Chang SL, Fishbane N, Davicioni E, Hartman L, Holmberg E, Feng FY, Speers C, Pierce LJ, Malmström P, Fernö M, Karlsson P.

Clin Cancer Res. 2019 Sep 26. pii: clincanres.1038.2019. doi: 10.1158/1078-0432.CCR-19-1038. [Epub ahead of print]

PMID:
31558478
3.

Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer.

Lundgren C, Bendahl PO, Borg Å, Ehinger A, Hegardt C, Larsson C, Loman N, Malmberg M, Olofsson H, Saal LH, Sjöblom T, Lindman H, Klintman M, Häkkinen J, Vallon-Christersson J, Fernö M, Rydén L, Ekholm M.

Breast Cancer Res Treat. 2019 Aug 20. doi: 10.1007/s10549-019-05378-7. [Epub ahead of print]

PMID:
31432367
4.

Refinement of breast cancer molecular classification by miRNA expression profiles.

Søkilde R, Persson H, Ehinger A, Pirona AC, Fernö M, Hegardt C, Larsson C, Loman N, Malmberg M, Rydén L, Saal L, Borg Å, Vallon-Christerson J, Rovira C.

BMC Genomics. 2019 Jun 17;20(1):503. doi: 10.1186/s12864-019-5887-7.

5.

Effect of Radiotherapy After Breast-Conserving Surgery Depending on the Presence of Tumor-Infiltrating Lymphocytes: A Long-Term Follow-Up of the SweBCG91RT Randomized Trial.

Kovács A, Stenmark Tullberg A, Werner Rönnerman E, Holmberg E, Hartman L, Sjöström M, Lundstedt D, Malmström P, Fernö M, Karlsson P.

J Clin Oncol. 2019 May 10;37(14):1179-1187. doi: 10.1200/JCO.18.02157. Epub 2019 Apr 2.

PMID:
30939091
6.

The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast.

Narbe U, Sjöström M, Forsare C, Bendahl PO, Alkner S, Leeb-Lundberg LMF, Lövgren K, Rydén L, Ingvar C, Fernö M.

Breast Cancer Res Treat. 2019 Jun;175(2):305-316. doi: 10.1007/s10549-019-05138-7. Epub 2019 Feb 22.

7.

Effects of adjuvant tamoxifen over three decades on breast cancer-free and distant recurrence-free interval among premenopausal women with oestrogen receptor-positive breast cancer randomised in the Swedish SBII:2pre trial.

Ekholm M, Bendahl PO, Fernö M, Nordenskjöld B, Stål O, Rydén L; South Swedish and South-East Swedish Breast Cancer Groups.

Eur J Cancer. 2019 Mar;110:53-61. doi: 10.1016/j.ejca.2018.12.034. Epub 2019 Feb 12.

8.

Non-linear transformations of age at diagnosis, tumor size, and number of positive lymph nodes in prediction of clinical outcome in breast cancer.

Forsare C, Bak M, Falck AK, Grabau D, Killander F, Malmström P, Rydén L, Stål O, Sundqvist M, Bendahl PO, Fernö M.

BMC Cancer. 2018 Dec 7;18(1):1226. doi: 10.1186/s12885-018-5123-x.

9.

Mechanisms of multiphase reactive flow using biogenically calcite-functionalized micromodels.

Song W, Ogunbanwo F, Steinsbø M, Fernø MA, Kovscek AR.

Lab Chip. 2018 Dec 4;18(24):3881-3891. doi: 10.1039/c8lc00793d.

PMID:
30462124
10.

Pillars or Pancakes? Self-Cleaning Surfaces without Coating.

Akhtar N, Thomas PJ, Svardal B, Almenningen S, de Jong E, Magnussen S, Onck PR, Fernø MA, Holst B.

Nano Lett. 2018 Dec 12;18(12):7509-7514. doi: 10.1021/acs.nanolett.8b02982. Epub 2018 Nov 9.

PMID:
30365888
11.

Stability of oestrogen and progesterone receptor antigenicity in formalin-fixed paraffin-embedded breast cancer tissue over time.

Ehinger A, Bendahl PO, Rydén L, Fernö M, Alkner S.

APMIS. 2018 Sep;126(9):746-754. doi: 10.1111/apm.12884.

PMID:
30160021
12.

Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors.

Sjöström M, Staaf J, Edén P, Wärnberg F, Bergh J, Malmström P, Fernö M, Niméus E, Fredriksson I.

Breast Cancer Res. 2018 Jul 4;20(1):64. doi: 10.1186/s13058-018-0978-y.

13.

Macrophage-derived lipocalin-2 transports iron in the tumor microenvironment.

Mertens C, Mora J, Ören B, Grein S, Winslow S, Scholich K, Weigert A, Malmström P, Forsare C, Fernö M, Schmid T, Brüne B, Jung M.

Oncoimmunology. 2017 Dec 22;7(3):e1408751. doi: 10.1080/2162402X.2017.1408751. eCollection 2018.

14.

Immune gene expression and response to chemotherapy in advanced breast cancer.

Foukakis T, Lövrot J, Matikas A, Zerdes I, Lorent J, Tobin N, Suzuki C, Brage SE, Carlsson L, Einbeigi Z, Linderholm B, Loman N, Malmberg M, Fernö M, Skoog L, Bergh J, Hatschek T.

Br J Cancer. 2018 Feb 20;118(4):480-488. doi: 10.1038/bjc.2017.446. Epub 2018 Jan 25.

15.

Determination of pore-scale hydrate phase equilibria in sediments using lab-on-a-chip technology.

Almenningen S, Flatlandsmo J, Kovscek AR, Ersland G, Fernø MA.

Lab Chip. 2017 Nov 21;17(23):4070-4076. doi: 10.1039/c7lc00719a.

PMID:
29067399
16.

PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients.

Tobin NP, Lundberg A, Lindström LS, Harrell JC, Foukakis T, Carlsson L, Einbeigi Z, Linderholm BK, Loman N, Malmberg M, Fernö M, Czene K, Perou CM, Bergh J, Hatschek T; TEX Trialists Group.

Clin Cancer Res. 2017 Dec 1;23(23):7225-7231. doi: 10.1158/1078-0432.CCR-17-2301. Epub 2017 Sep 29.

17.

Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial.

Kimbung S, Markholm I, Bjöhle J, Lekberg T, von Wachenfeldt A, Azavedo E, Saracco A, Hellström M, Veerla S, Paquet E, Bendahl PO, Fernö M, Bergh J, Loman N, Hatschek T, Hedenfalk I; PROMIX Trialists Group.

Int J Cancer. 2018 Feb 1;142(3):618-628. doi: 10.1002/ijc.31070. Epub 2017 Oct 13.

18.

Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98.

Alkner S, Jensen MB, Rasmussen BB, Bendahl PO, Fernö M, Rydén L, Mouridsen H; Danish Breast Cancer Cooperative Group.

Breast Cancer Res Treat. 2017 Nov;166(2):481-490. doi: 10.1007/s10549-017-4416-0. Epub 2017 Aug 1.

19.

Response to Radiotherapy After Breast-Conserving Surgery in Different Breast Cancer Subtypes in the Swedish Breast Cancer Group 91 Radiotherapy Randomized Clinical Trial.

Sjöström M, Lundstedt D, Hartman L, Holmberg E, Killander F, Kovács A, Malmström P, Niméus E, Werner Rönnerman E, Fernö M, Karlsson P.

J Clin Oncol. 2017 Oct 1;35(28):3222-3229. doi: 10.1200/JCO.2017.72.7263. Epub 2017 Jul 31.

PMID:
28759347
20.

Tumor tissue protein signatures reflect histological grade of breast cancer.

Skoog P, Ohlsson M, Fernö M, Rydén L, Borrebaeck CAK, Wingren C.

PLoS One. 2017 Jun 26;12(6):e0179775. doi: 10.1371/journal.pone.0179775. eCollection 2017.

21.

Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.

Ehinger A, Malmström P, Bendahl PO, Elston CW, Falck AK, Forsare C, Grabau D, Rydén L, Stål O, Fernö M; South and South-East Swedish Breast Cancer Groups.

Acta Oncol. 2017 Jan;56(1):68-74. doi: 10.1080/0284186X.2016.1237778. Epub 2016 Oct 20.

PMID:
27762648
22.

Two Years of Adjuvant Tamoxifen Provides a Survival Benefit Compared With No Systemic Treatment in Premenopausal Patients With Primary Breast Cancer: Long-Term Follow-Up (> 25 years) of the Phase III SBII:2pre Trial.

Ekholm M, Bendahl PO, Fernö M, Nordenskjöld B, Stål O, Rydén L.

J Clin Oncol. 2016 Jul 1;34(19):2232-8. doi: 10.1200/JCO.2015.65.6272. Epub 2016 May 9.

23.

Prior Adjuvant Tamoxifen Treatment in Breast Cancer Is Linked to Increased AIB1 and HER2 Expression in Metachronous Contralateral Breast Cancer.

Alkner S, Bendahl PO, Ehinger A, Lövgren K, Rydén L, Fernö M.

PLoS One. 2016 Mar 9;11(3):e0150977. doi: 10.1371/journal.pone.0150977. eCollection 2016.

24.

St Gallen molecular subtypes in screening-detected and symptomatic breast cancer in a prospective cohort with long-term follow-up.

Falck AK, Röme A, Fernö M, Olsson H, Chebil G, Bendahl PO, Rydén L.

Br J Surg. 2016 Apr;103(5):513-23. doi: 10.1002/bjs.10070. Epub 2016 Feb 9.

25.

Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications.

Kimbung S, Kovács A, Danielsson A, Bendahl PO, Lövgren K, Frostvik Stolt M, Tobin NP, Lindström L, Bergh J, Einbeigi Z, Fernö M, Hatschek T, Hedenfalk I.

Oncotarget. 2015 Oct 20;6(32):33306-18. doi: 10.18632/oncotarget.5089.

26.

Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis-Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer.

Kimbung S, Johansson I, Danielsson A, Veerla S, Egyhazi Brage S, Frostvik Stolt M, Skoog L, Carlsson L, Einbeigi Z, Lidbrink E, Linderholm B, Loman N, Malmström PO, Söderberg M, Walz TM, Fernö M, Hatschek T, Hedenfalk I; TEX study group.

Clin Cancer Res. 2016 Jan 1;22(1):146-57. doi: 10.1158/1078-0432.CCR-15-0487. Epub 2015 Aug 14.

27.

Protease Activated Receptors 1 and 2 Correlate Differently with Breast Cancer Aggressiveness Depending on Tumor ER Status.

Lidfeldt J, Bendahl PO, Forsare C, Malmström P, Fernö M, Belting M.

PLoS One. 2015 Aug 5;10(8):e0134932. doi: 10.1371/journal.pone.0134932. eCollection 2015.

28.

Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy.

Alkner S, Ehinger A, Bendahl PO, Rydén L, Fernö M.

Eur J Cancer. 2015 Nov;51(16):2304-13. doi: 10.1016/j.ejca.2015.07.016. Epub 2015 Aug 1.

PMID:
26243193
29.

Contralateral breast cancer can represent a metastatic spread of the first primary tumor: determination of clonal relationship between contralateral breast cancers using next-generation whole genome sequencing.

Alkner S, Tang MH, Brueffer C, Dahlgren M, Chen Y, Olsson E, Winter C, Baker S, Ehinger A, Rydén L, Saal LH, Fernö M, Gruvberger-Saal SK.

Breast Cancer Res. 2015 Aug 5;17:102. doi: 10.1186/s13058-015-0608-x.

30.

Stem cell biomarker ALDH1A1 in breast cancer shows an association with prognosis and clinicopathological variables that is highly cut-off dependent.

Sjöström M, Hartman L, Honeth G, Grabau D, Malmström P, Hegardt C, Fernö M, Niméus E.

J Clin Pathol. 2015 Dec;68(12):1012-9. doi: 10.1136/jclinpath-2015-203092. Epub 2015 Jul 14.

PMID:
26175266
31.

Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease.

Olsson E, Winter C, George A, Chen Y, Howlin J, Tang MH, Dahlgren M, Schulz R, Grabau D, van Westen D, Fernö M, Ingvar C, Rose C, Bendahl PO, Rydén L, Borg Å, Gruvberger-Saal SK, Jernström H, Saal LH.

EMBO Mol Med. 2015 Aug;7(8):1034-47. doi: 10.15252/emmm.201404913.

32.

Highly reproducible results of breast cancer biomarkers when analysed in accordance with national guidelines - a Swedish survey with central re-assessment.

Ekholm M, Grabau D, Bendahl PO, Bergh J, Elmberger G, Olsson H, Russo L, Viale G, Fernö M.

Acta Oncol. 2015 Jul;54(7):1040-8. doi: 10.3109/0284186X.2015.1037012. Epub 2015 May 11.

PMID:
25959664
33.

Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance.

Busch S, Sims AH, Stål O, Fernö M, Landberg G.

Cancer Res. 2015 Apr 1;75(7):1457-69. doi: 10.1158/0008-5472.CAN-14-1583.

34.

A Molecular Pathologic Framework for Risk Stratification of Stage T1 Urothelial Carcinoma.

Patschan O, Sjödahl G, Chebil G, Lövgren K, Lauss M, Gudjonsson S, Kollberg P, Eriksson P, Aine M, Månsson W, Fernö M, Liedberg F, Höglund M.

Eur Urol. 2015 Nov;68(5):824-32; discussion 835-6. doi: 10.1016/j.eururo.2015.02.021. Epub 2015 Mar 11.

PMID:
25770486
35.

Association between insulin-like growth factor-1 receptor (IGF1R) negativity and poor prognosis in a cohort of women with primary breast cancer.

Aaltonen KE, Rosendahl AH, Olsson H, Malmström P, Hartman L, Fernö M.

BMC Cancer. 2014 Nov 3;14:794. doi: 10.1186/1471-2407-14-794.

36.

Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival.

Tobin NP, Harrell JC, Lövrot J, Egyhazi Brage S, Frostvik Stolt M, Carlsson L, Einbeigi Z, Linderholm B, Loman N, Malmberg M, Walz T, Fernö M, Perou CM, Bergh J, Hatschek T, Lindström LS; TEX Trialists Group.

Ann Oncol. 2015 Jan;26(1):81-8. doi: 10.1093/annonc/mdu498. Epub 2014 Oct 31.

37.

The three receptor tyrosine kinases c-KIT, VEGFR2 and PDGFRα, closely spaced at 4q12, show increased protein expression in triple-negative breast cancer.

Jansson S, Bendahl PO, Grabau DA, Falck AK, Fernö M, Aaltonen K, Rydén L.

PLoS One. 2014 Jul 15;9(7):e102176. doi: 10.1371/journal.pone.0102176. eCollection 2014.

38.

A novel model for Ki67 assessment in breast cancer.

Romero Q, Bendahl PO, Fernö M, Grabau D, Borgquist S.

Diagn Pathol. 2014 Jun 16;9:118. doi: 10.1186/1746-1596-9-118.

39.

Infiltration of CD3⁺ and CD68⁺ cells in bladder cancer is subtype specific and affects the outcome of patients with muscle-invasive tumors.

Sjödahl G, Lövgren K, Lauss M, Chebil G, Patschan O, Gudjonsson S, Månsson W, Fernö M, Leandersson K, Lindgren D, Liedberg F, Höglund M.

Urol Oncol. 2014 Aug;32(6):791-7. doi: 10.1016/j.urolonc.2014.02.007. Epub 2014 Apr 29.

40.

Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer.

Sjöström M, Hartman L, Grabau D, Fornander T, Malmström P, Nordenskjöld B, Sgroi DC, Skoog L, Stål O, Leeb-Lundberg LM, Fernö M.

Breast Cancer Res Treat. 2014 May;145(1):61-71. doi: 10.1007/s10549-014-2936-4. Epub 2014 Apr 9.

PMID:
24715381
41.

Invasive lobular carcinoma of the breast: long-term prognostic value of Ki67 and histological grade, alone and in combination with estrogen receptor.

Narbe U, Bendahl PO, Grabau D, Rydén L, Ingvar C, Fernö M.

Springerplus. 2014 Feb 6;3:70. doi: 10.1186/2193-1801-3-70. eCollection 2014.

42.

Immunohistochemical assessment of Ki67 with antibodies SP6 and MIB1 in primary breast cancer: a comparison of prognostic value and reproducibility.

Ekholm M, Beglerbegovic S, Grabau D, Lövgren K, Malmström P, Hartman L, Fernö M.

Histopathology. 2014 Aug;65(2):252-60. doi: 10.1111/his.12392. Epub 2014 May 16.

PMID:
24527721
43.

The prognostic value of mitotic activity index (MAI), phosphohistone H3 (PPH3), cyclin B1, cyclin A, and Ki67, alone and in combinations, in node-negative premenopausal breast cancer.

Klintman M, Strand C, Ahlin C, Beglerbegovic S, Fjällskog ML, Grabau D, Gudlaugsson E, Janssen EA, Lövgren K, Skaland I, Bendahl PO, Malmström P, Baak JP, Fernö M.

PLoS One. 2013 Dec 4;8(12):e81902. doi: 10.1371/journal.pone.0081902. eCollection 2013.

44.

Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences.

Kimbung S, Kovács A, Bendahl PO, Malmström P, Fernö M, Hatschek T, Hedenfalk I.

Mol Oncol. 2014 Feb;8(1):119-28. doi: 10.1016/j.molonc.2013.10.002. Epub 2013 Oct 14.

46.

Grading breast cancer tissues using molecular portraits.

Olsson N, Carlsson P, James P, Hansson K, Waldemarson S, Malmström P, Fernö M, Ryden L, Wingren C, Borrebaeck CA.

Mol Cell Proteomics. 2013 Dec;12(12):3612-23. doi: 10.1074/mcp.M113.030379. Epub 2013 Aug 27.

47.

Toward a molecular pathologic classification of urothelial carcinoma.

Sjödahl G, Lövgren K, Lauss M, Patschan O, Gudjonsson S, Chebil G, Aine M, Eriksson P, Månsson W, Lindgren D, Fernö M, Liedberg F, Höglund M.

Am J Pathol. 2013 Sep;183(3):681-91. doi: 10.1016/j.ajpath.2013.05.013. Epub 2013 Jul 1.

48.

Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.

Falck AK, Bendahl PO, Chebil G, Olsson H, Fernö M, Rydén L.

Breast Cancer Res Treat. 2013 Jul;140(1):93-104. doi: 10.1007/s10549-013-2617-8. Epub 2013 Jun 27.

PMID:
23807420
49.

Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial.

Bjöhle J, Bergqvist J, Gronowitz JS, Johansson H, Carlsson L, Einbeigi Z, Linderholm B, Loman N, Malmberg M, Söderberg M, Sundquist M, Walz TM, Fernö M, Bergh J, Hatschek T.

Breast Cancer Res Treat. 2013 Jun;139(3):751-8. doi: 10.1007/s10549-013-2579-x. Epub 2013 Jun 5.

PMID:
23736998
50.

A prospective, multicenter validation study of a prognostic index composed of S-phase fraction, progesterone receptor status, and tumour size predicts survival in node-negative breast cancer patients: NNBC, the node-negative breast cancer trial.

Klintman M, Nilsson F, Bendahl PO, Fernö M, Liljegren G, Emdin S, Malmström P; Swedish Breast Cancer Group.

Ann Oncol. 2013 Sep;24(9):2284-91. doi: 10.1093/annonc/mdt186. Epub 2013 May 23.

PMID:
23704202

Supplemental Content

Support Center